Scientists test new drug duo to fight tough cancers
NCT ID NCT04705818
Summary
This study tested whether combining an immunotherapy drug (durvalumab) with an epigenetic drug (tazemetostat) could help control advanced solid tumors. It enrolled 164 adults with specific advanced cancers, including pancreatic, colorectal, and soft-tissue sarcoma, who had run out of standard treatment options. The main goal was to see if this new combination could stop or shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU Brest
Brest, 29200, France
-
CHU Poitiers
Poitiers, 86000, France
-
Institut Bergonie
Bordeaux, 33076, France
Conditions
Explore the condition pages connected to this study.